BioSpace News Archive

Deals

Biogen Boosts Neuro Pipeline with $7.3B Reata Buy Amid Layoffs

Following a sweeping cost-cutting plan announced earlier this week, including an 11% workforce reduction, Biogen is acquiring Reata Pharmaceuticals to bolster its neurological and rare disease pipeline.

July 28, 2023
·
2 min read
·
Tristan Manalac
Drug Development

Merck’s Pneumococcal Shot Claims Back-to-Back Phase III Wins

Two late-stage trial wins for Merck’s V116 investigational pneumococcal vaccine could make it a serious challenger to Pfizer’s Prevnar 20 in the space.

July 28, 2023
·
2 min read
·
Tristan Manalac
Drug Development

Week in Review: Biogen M&A and Layoffs, Earnings Season Heats Up, and 12 Neuro Companies to Watch

Biogen’s $7.3 billion Reata acquisition and layoffs dominated this week’s news, while BMS and Roche reported second-quarter earnings and BioSpace looked at 12 late-stage neuro companies.

July 28, 2023
·
2 min read
·
Greg Slabodkin
Business

AstraZeneca, Pfizer Ink Potential $1B Gene Therapy Deal

The British drugmaker’s rare disease subsidiary Alexion will take on a number of Pfizer’s preclinical gene therapy programs and technologies to advance its genomic medicines pipeline.

July 28, 2023
·
2 min read
·
Kate Goodwin
Sana Biotechnology Advances R&D Platform to Overcome Immune Rejection

With its hypoimmune technology, the company looks to reshape the future of cell and gene therapy.

July 28, 2023
·
5 min read
·
Caleigh Findley
Drug Development

Takeda Likely to Drop Rare Genetic Disease Candidate After Phase II Fail

Despite beating analyst expectations, Takeda sustains a mid-stage defeat in a rare genetic disorder, leaving the fate of an investigational enzyme replacement therapy uncertain.

July 28, 2023
·
2 min read
·
Tristan Manalac
Deals

Press Release: Sanofi to acquire Qunol®, a fast-growing U.S. brand in the healthy aging segment

Paris, July28, 2023. Sanofi announces it has entered into a definitive agreement to acquire ownership of Qunol®, a U.S.-based, market-leading brand in health & wellness.

July 28, 2023
·
6 min read
Job Trends

Press Release: Solid Q2 performance and strong pipeline momentum, Full-year 2023 business EPS guidance raised

Vaccines up 9.1% due to strong PPH vaccines sales in Rest of World region and COVID vaccine supply in Europe.

July 28, 2023
·
3 min read
Drug Development

Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments

Genenta Science announced that the Phase 1 dose-ranging clinical trial in Glioblastoma Multiforme (TEM1-GBM) is progressing in line with the development program.

July 28, 2023
·
4 min read
Biotech Bay

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - July 28, 2023

IDEAYA Biosciences, Inc. announced that, on July 27, 2023, the Compensation Committee of IDEAYA’s Board of Directors granted non-qualified stock options to purchase an aggregate of 51,200 shares of the Company’s common stock to two newly hired employees.

July 28, 2023
·
2 min read